Fig. 7

The doublet regimen of FAK inhibition and PLD enhances the treatment outcome of ICB. A The schedule for the ID8-Luc study. B-D The triple combination testing including IN10018, PLD, and anti-mouse PD-L1 in the treatment of ID8 Luc model. IN10018 were dosed through oral gavage once daily. PLD was dosed by teil vein injection once a week and anti-mouse PD-L1 was intraperitoneally administered twice a week. The dosing was stopped at day 28. The survival curves of no ascites formation rate were prepared using GraphPad Prism 8.0 software (B). The abdominal girth (C) and body weights (D) were recorded weekly. Data represent mean ± SEM. Statistical analysis was done using one-way ANOVA for the CT26 study. Log-rank test was performed for the ID8-Luc study. *P < 0.05, and ***P < 0.001. E Schematic model for the optimized anticancer effects of ICB boosted by the ICD from IN10018 plus PLD